US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Therapeutics

39.68

-0.3200-0.80%

Post-market: 39.28-0.4000-1.01%19:57 EDT

Volume:614.67K

Turnover:24.44M

Market Cap:1.13B

PE:-20.90

High:40.50

Open:40.00

Low:38.82

Close:40.00

52wk High:41.70

52wk Low:16.54

Shares:28.52M

Float Shares:13.13M

Volume Ratio:1.16

T/O Rate:4.68%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.8984

EPS(LYR):-2.3387

ROE:-26.25%

ROA:-18.44%

PB:5.48

PE(LYR):-16.97

Loading ...

Overview Company News Filings

Oruka Therapeutics initiated with a Buy at Clear Street

Windtree Therapeutics to Be Delisted from NASDAQ for Failing to Meet Minimum Closing Price Standards

BioGene Therapeutics Appoints Dr. Kamal Albarazanji to Boost Metabolic Research

Windtree Therapeutics Faces Nasdaq Delisting Notice

Enlivex Therapeutics’ Phase 2 Study on Allocetra-OTS for Sepsis: Key Insights for Investors

Keros Therapeutics Gets FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Treatment

MT Newswires Live

Keros Therapeutics granted Orphan Drug designation for KER-065 in DMD

Intensity Therapeutics Is Maintained at Speculative Buy by Benchmark

Aligos Therapeutics appoints Ramon Polo as head of global regulatory affairs

Iterum Therapeutics Launches New Antibiotic ORLYNVAH

Press Release: Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs

Press Release: HLS Therapeutics Announces New Credit Agreement

Knight Therapeutics Gets Exchange Approval for Share Buyback Program

Iterum Therapeutics announces U.S. commercial launch of ORLYNVAH

Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S.

Intensity Therapeutics price target lowered to $1.50 from $4 at Benchmark

Prescient Therapeutics Releases Corporate Governance Statement

Prescient Therapeutics Reports Financial Results with Focus on R&D Investment

Neurizon Therapeutics Says ALS Drug Candidate Study Confirms Long-Term Treatment at Recommended Dose is Safe, Well-Tolerated

MT Newswires Live

Infant Bacterial Therapeutics Advances Toward Launch of Breakthrough Infant Drug

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/LENZ/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LENZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":39.68,"timestamp":1756152000000,"preClose":40,"halted":0,"volume":614667,"hourTrading":{"tag":"盘后","latestPrice":39.28,"preClose":39.68,"latestTime":"19:57 EDT","volume":3541,"amount":140244.06,"timestamp":1756166236694},"delay":0,"floatShares":13134810,"shares":28522096,"eps":-1.898372,"marketStatus":"Not Yet Opened","change":-0.32,"latestTime":"08-25 16:00:00 EDT","open":40,"high":40.5,"low":38.815,"amount":24435960.578265,"amplitude":0.042125,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.898372,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1756195200000},"marketStatusCode":0,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":40,"preHourTrading":{"tag":"盘前","latestPrice":40,"preClose":40,"latestTime":"09:27 EDT","volume":300800,"amount":12031724.467200002,"timestamp":1756128420047},"postHourTrading":{"tag":"盘后","latestPrice":39.28,"preClose":39.68,"latestTime":"19:57 EDT","volume":3541,"amount":140244.06,"timestamp":1756166236694},"volumeRatio":1.162023,"impliedVol":0.8322,"impliedVolPercentile":0.7263},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","floatShares":13134810,"roa":"-18.44%","roe":"-26.25%","lyrEps":-2.338654,"volumeRatio":1.162023,"shares":28522096,"dividePrice":0,"high":40.5,"amplitude":0.042125,"preClose":40,"low":38.815,"week52Low":16.535,"pbRate":"5.48","psRate":"226.35","week52High":41.7,"institutionHeld":0,"latestPrice":39.68,"eps":-1.898372,"divideRate":0,"volume":614667,"delay":0,"ttmEps":-1.898372,"open":40,"prevYearClose":28.87,"prevWeekClose":40,"prevMonthClose":29.77,"prevQuarterClose":29.31,"fiveDayClose":38.77,"twentyDayClose":31.51,"sixtyDayClose":29.53},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LENZ\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-07-30","symbol":"LENZ","fiscalQuarterEnding":"2025/06","expectedEps":-0.58,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1753848000000,"reportTimeType":"pre","actualEps":-0.53},{"market":"US","date":"2024-05-08","symbol":"LENZ","fiscalQuarterEnding":"2024/03","expectedEps":-0.84,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715140800000,"reportTimeType":"pre","actualEps":-3.53},{"market":"US","date":"2024-03-22","symbol":"LENZ","defaultRemindTime":1711114200000,"type":"split","dateTimestamp":1711080000000,"forFactor":7,"toFactor":1,"ratio":7},{"date":"2024-03-22","symbol":"LENZ","amount":1.03,"announcedDate":null,"type":"dividend","market":"US","newRecordDate":"2024-03-18","name":"Therapeutics","recordDate":"2024-03-21","payableDate":"2024-03-18","currency":"USD","dateTimestamp":1711080000000,"payDate":"2024-03-21"},{"market":"US","date":"2021-08-12","symbol":"LENZ","fiscalQuarterEnding":"2021/06","expectedEps":-1.11,"name":null,"time":"","type":"earning","dateTimestamp":1628740800000,"reportTimeType":"","actualEps":-3.45}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LENZ\",market:\"US\",,,undefined,":[{"executeDate":"2024-03-22","recordDate":"2024-03-18","paymentDate":"2024-03-21","value":1.03,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LENZ\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":8,"updateTime":1742443200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LENZ\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LENZ","date":"2025-08-22","current":-21.691773,"percent":0.002985,"low":-22.268769,"twenty":-16.434778,"median":-11.220775,"eighty":-7.693556,"high":-5.069183,"avg":-11.98188,"sd":4.459531,"marketCap":1136605525},"quantilePoints":[{"date":"2024-03-28","current":-7.959158,"twenty":-7.219077,"median":-6.108955,"eighty":-6.016992,"marketCap":556886354},{"date":"2024-04-05","current":-7.492045,"twenty":-7.873034,"median":-7.667213,"eighty":-6.662191,"marketCap":524203432},{"date":"2024-04-12","current":-7.929963,"twenty":-7.855517,"median":-7.667213,"eighty":-7.432197,"marketCap":554843672},{"date":"2024-04-19","current":-6.382653,"twenty":-7.855517,"median":-7.488396,"eighty":-6.783348,"marketCap":446581492},{"date":"2024-04-26","current":-5.638193,"twenty":-7.716113,"median":-7.451903,"eighty":-5.889996,"marketCap":394493084},{"date":"2024-05-03","current":-5.988527,"twenty":-7.671592,"median":-6.864363,"eighty":-5.803142,"marketCap":419005276},{"date":"2024-05-10","current":-5.317808,"twenty":-7.667213,"median":-6.108955,"eighty":-5.803142,"marketCap":393230653},{"date":"2024-05-17","current":-5.708011,"twenty":-7.597146,"median":-6.0013,"eighty":-5.749862,"marketCap":422084590},{"date":"2024-05-24","current":-5.428308,"twenty":-7.489126,"median":-6.006774,"eighty":-5.719496,"marketCap":401401679},{"date":"2024-05-31","current":-5.355793,"twenty":-7.479638,"median":-5.988527,"eighty":-5.522773,"marketCap":396039443},{"date":"2024-06-07","current":-5.193496,"twenty":-7.457742,"median":-5.904593,"eighty":-5.428999,"marketCap":384038248},{"date":"2024-06-14","current":-6.433167,"twenty":-7.451903,"median":-5.930138,"eighty":-5.428308,"marketCap":475706952},{"date":"2024-06-21","current":-6.236339,"twenty":-7.425628,"median":-5.992177,"eighty":-5.43107,"marketCap":461152311},{"date":"2024-06-28","current":-6.150011,"twenty":-7.389135,"median":-6.0013,"eighty":-5.439358,"marketCap":454768696},{"date":"2024-07-05","current":-6.098214,"twenty":-7.269437,"median":-6.014073,"eighty":-5.469746,"marketCap":450938528},{"date":"2024-07-12","current":-6.771573,"twenty":-6.771573,"median":-6.098214,"eighty":-5.493918,"marketCap":500730721},{"date":"2024-07-15","current":-7.261916,"twenty":-7.163847,"median":-6.103393,"eighty":-5.509112,"marketCap":536989651},{"date":"2024-08-02","current":-8.498134,"twenty":-7.266429,"median":-6.108573,"eighty":-5.524305,"marketCap":628403011},{"date":"2024-08-09","current":-8.328931,"twenty":-7.474529,"median":-6.146558,"eighty":-5.597209,"marketCap":615891126},{"date":"2024-08-16","current":-8.944708,"twenty":-7.671592,"median":-6.236339,"eighty":-5.641258,"marketCap":621424629},{"date":"2024-08-23","current":-8.79431,"twenty":-7.94748,"median":-6.352018,"eighty":-5.670717,"marketCap":610975896},{"date":"2024-08-30","current":-8.746816,"twenty":-8.006409,"median":-6.382653,"eighty":-5.719496,"marketCap":607676296},{"date":"2024-09-06","current":-9.451311,"twenty":-8.199004,"median":-6.419354,"eighty":-5.743293,"marketCap":656620360},{"date":"2024-09-13","current":-8.17293,"twenty":-8.352945,"median":-6.434893,"eighty":-5.773217,"marketCap":567806132},{"date":"2024-09-20","current":-8.7389,"twenty":-8.507104,"median":-6.459289,"eighty":-5.788545,"marketCap":607126363},{"date":"2024-09-27","current":-8.806184,"twenty":-8.638371,"median":-6.616182,"eighty":-5.792924,"marketCap":611800796},{"date":"2024-10-04","current":-8.897214,"twenty":-8.745233,"median":-7.269437,"eighty":-5.800953,"marketCap":618125029},{"date":"2024-10-11","current":-9.340491,"twenty":-8.850511,"median":-7.455552,"eighty":-5.81701,"marketCap":648921294},{"date":"2024-10-18","current":-10.417023,"twenty":-8.905129,"median":-7.492045,"eighty":-5.857882,"marketCap":723712222},{"date":"2024-10-25","current":-9.902504,"twenty":-9.0017,"median":-7.670862,"eighty":-5.904593,"marketCap":687966558},{"date":"2024-10-31","current":-10.939457,"twenty":-9.257377,"median":-7.718702,"eighty":-5.904593,"marketCap":760007820},{"date":"2024-11-08","current":-14.709443,"twenty":-9.419648,"median":-7.959158,"eighty":-5.955683,"marketCap":894466512},{"date":"2024-11-15","current":-15.344855,"twenty":-9.514636,"median":-8.00261,"eighty":-5.970448,"marketCap":933105265},{"date":"2024-11-22","current":-15.521232,"twenty":-9.76398,"median":-8.132103,"eighty":-5.988527,"marketCap":943830613},{"date":"2024-11-29","current":-16.100113,"twenty":-9.924668,"median":-8.17293,"eighty":-5.994366,"marketCap":979031755},{"date":"2024-12-06","current":-16.33076,"twenty":-10.388526,"median":-8.285117,"eighty":-6.004584,"marketCap":993057210},{"date":"2024-12-13","current":-13.920266,"twenty":-10.815972,"median":-8.351032,"eighty":-6.018452,"marketCap":846477455},{"date":"2024-12-20","current":-13.694141,"twenty":-11.182468,"median":-8.50374,"eighty":-6.082845,"marketCap":832727009},{"date":"2024-12-27","current":-14.476534,"twenty":-12.093039,"median":-8.531114,"eighty":-6.098214,"marketCap":880303552},{"date":"2025-01-03","current":-12.794163,"twenty":-13.449021,"median":-8.618187,"eighty":-6.102358,"marketCap":778000234},{"date":"2025-01-10","current":-11.912274,"twenty":-13.190334,"median":-8.707238,"eighty":-6.108649,"marketCap":724373495},{"date":"2025-01-17","current":-10.130408,"twenty":-13.019383,"median":-8.746816,"eighty":-6.115785,"marketCap":616019980},{"date":"2025-01-24","current":-11.197719,"twenty":-12.871045,"median":-8.79431,"eighty":-6.143105,"marketCap":680922085},{"date":"2025-01-31","current":-11.523339,"twenty":-12.794163,"median":-8.877425,"eighty":-6.150011,"marketCap":700722728},{"date":"2025-02-07","current":-12.070562,"twenty":-12.328345,"median":-8.905129,"eighty":-6.232886,"marketCap":733998807},{"date":"2025-02-14","current":-11.432889,"twenty":-12.292165,"median":-8.964497,"eighty":-6.236339,"marketCap":695222549},{"date":"2025-02-21","current":-11.279124,"twenty":-12.151063,"median":-8.998138,"eighty":-6.308164,"marketCap":685872246},{"date":"2025-02-28","current":-9.62841,"twenty":-12.079607,"median":-9.059485,"eighty":-6.342695,"marketCap":585493990},{"date":"2025-03-07","current":-10.297741,"twenty":-11.943932,"median":-9.320702,"eighty":-6.355126,"marketCap":626195310},{"date":"2025-03-14","current":-11.193196,"twenty":-11.879712,"median":-9.419648,"eighty":-6.365485,"marketCap":680647077},{"date":"2025-03-21","current":-14.554795,"twenty":-11.943932,"median":-9.482973,"eighty":-6.379634,"marketCap":724377586},{"date":"2025-03-28","current":-14.68208,"twenty":-12.421509,"median":-9.574004,"eighty":-6.398202,"marketCap":730712447},{"date":"2025-04-04","current":-12.728528,"twenty":-13.089934,"median":-9.668992,"eighty":-6.415901,"marketCap":633486102},{"date":"2025-04-11","current":-10.2603,"twenty":-12.90813,"median":-9.741473,"eighty":-6.42488,"marketCap":510644883},{"date":"2025-04-17","current":-12.761733,"twenty":-12.945214,"median":-9.779811,"eighty":-6.430405,"marketCap":635138674},{"date":"2025-04-25","current":-15.833323,"twenty":-13.271407,"median":-9.84549,"eighty":-6.435239,"marketCap":788008663},{"date":"2025-05-02","current":-15.982746,"twenty":-13.932929,"median":-9.940463,"eighty":-6.440764,"marketCap":795445305},{"date":"2025-05-09","current":-15.25222,"twenty":-14.136351,"median":-10.102399,"eighty":-6.452984,"marketCap":728141003},{"date":"2025-05-16","current":-16.118891,"twenty":-14.245886,"median":-10.138549,"eighty":-6.460191,"marketCap":769515850},{"date":"2025-05-23","current":-16.637714,"twenty":-14.356129,"median":-10.19625,"eighty":-6.460792,"marketCap":794284465},{"date":"2025-05-30","current":-17.410053,"twenty":-14.523491,"median":-10.236057,"eighty":-6.585104,"marketCap":831155927},{"date":"2025-06-06","current":-17.864023,"twenty":-14.65894,"median":-10.342966,"eighty":-6.96771,"marketCap":852828466},{"date":"2025-06-13","current":-17.439532,"twenty":-14.747436,"median":-10.384797,"eighty":-7.264924,"marketCap":832563235},{"date":"2025-06-20","current":-17.704839,"twenty":-14.88454,"median":-10.454615,"eighty":-7.299361,"marketCap":845229004},{"date":"2025-06-27","current":-17.752005,"twenty":-15.005667,"median":-10.623361,"eighty":-7.425628,"marketCap":847480696},{"date":"2025-07-03","current":-19.178768,"twenty":-15.33581,"median":-10.694071,"eighty":-7.451903,"marketCap":915594389},{"date":"2025-07-11","current":-20.198727,"twenty":-15.529319,"median":-10.766979,"eighty":-7.459202,"marketCap":964287236},{"date":"2025-07-18","current":-20.381494,"twenty":-15.833323,"median":-10.791578,"eighty":-7.484747,"marketCap":973012543},{"date":"2025-07-25","current":-19.691695,"twenty":-16.100113,"median":-11.044571,"eighty":-7.492045,"marketCap":940081543},{"date":"2025-08-01","current":-16.20487,"twenty":-16.158905,"median":-11.077981,"eighty":-7.667213,"marketCap":849102797},{"date":"2025-08-08","current":-17.484059,"twenty":-16.20487,"median":-11.141188,"eighty":-7.667213,"marketCap":916129723},{"date":"2025-08-15","current":-22.268769,"twenty":-16.33076,"median":-11.193196,"eighty":-7.674511,"marketCap":1166838947},{"date":"2025-08-22","current":-21.691773,"twenty":-16.434778,"median":-11.220775,"eighty":-7.693556,"marketCap":1136605525}],"updateTime":1756189006292},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LENZ\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2561481750","title":"Oruka Therapeutics initiated with a Buy at Clear Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2561481750","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561481750?lang=en_us&edition=fundamental","pubTime":"2025-08-21 04:35","pubTimestamp":1755722116,"startTime":"0","endTime":"0","summary":"Clear Street analyst Kaveri Pohlman initiated coverage of Oruka Therapeutics (ORKA) with a Buy rating and $46 price target The firm views the stock...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oruka-therapeutics-initiated-with-a-buy-at-clear-street-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oruka-therapeutics-initiated-with-a-buy-at-clear-street-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","LENZ","ORKA","BK4539"],"gpt_icon":0},{"id":"1192236024","title":"Windtree Therapeutics to Be Delisted from NASDAQ for Failing to Meet Minimum Closing Price Standards","url":"https://stock-news.laohu8.com/highlight/detail?id=1192236024","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192236024?lang=en_us&edition=fundamental","pubTime":"2025-08-21 02:31","pubTimestamp":1755714689,"startTime":"0","endTime":"0","summary":"Windtree Therapeutics, dubbed the \"BNB MicroStrategy\" company, received notification from NASDAQ on August 19, 2025, that its common stock will be delisted from the NASDAQ Capital Market on August 21...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDX","LENZ","QID","ARTL","MNQmain","USAW.SI",".IXIC","BK1147","PSQ","BK4139","USJW.SI","BK4539","NQmain","TSYW.SI","SQQQ","QLD","BK4007","QQQ","03086","TQQQ","159632","NVIW.SI"],"gpt_icon":1},{"id":"2561839794","title":"BioGene Therapeutics Appoints Dr. Kamal Albarazanji to Boost Metabolic Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2561839794","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561839794?lang=en_us&edition=fundamental","pubTime":"2025-08-21 01:03","pubTimestamp":1755709409,"startTime":"0","endTime":"0","summary":"The latest announcement is out from PreveCeutical Medical ( ($TSE:PREV) ). PreveCeutical Medical Inc.’s subsidiary, BioGene Therapeutics Inc., has ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biogene-therapeutics-appoints-dr-kamal-albarazanji-to-boost-metabolic-research?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biogene-therapeutics-appoints-dr-kamal-albarazanji-to-boost-metabolic-research?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4539","BK4139","BK4007"],"gpt_icon":0},{"id":"2561370483","title":"Windtree Therapeutics Faces Nasdaq Delisting Notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2561370483","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561370483?lang=en_us&edition=fundamental","pubTime":"2025-08-21 00:48","pubTimestamp":1755708505,"startTime":"0","endTime":"0","summary":"The latest update is out from Windtree Therapeutics ( ($WINT) ). On August 19, 2025, Windtree Therapeutics Inc. was informed by Nasdaq of its decis...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/windtree-therapeutics-faces-nasdaq-delisting-notice?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/windtree-therapeutics-faces-nasdaq-delisting-notice?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["USAW.SI","LU2095319765.USD","MNQmain","USJW.SI","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2210149790.SGD","QLD",".IXIC","LU2210150020.SGD","SQQQ","LENZ","TQQQ","TSYW.SI","BK4139","QID","BK4007","LU0314104364.USD","NDAQ","NQmain","IE00B64PRP62.GBP","PSQ","BK4112","BK4585","NVIW.SI","BK4588","BK4539","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2561148853","title":"Enlivex Therapeutics’ Phase 2 Study on Allocetra-OTS for Sepsis: Key Insights for Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2561148853","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561148853?lang=en_us&edition=fundamental","pubTime":"2025-08-21 00:15","pubTimestamp":1755706555,"startTime":"0","endTime":"0","summary":"Enlivex Therapeutics (($ENLV)) announced an update on their ongoing clinical study. Study Overview: Enlivex Therapeutics is conducting a Phase 2 st...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/enlivex-therapeutics-phase-2-study-on-allocetra-ots-for-sepsis-key-insights-for-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/enlivex-therapeutics-phase-2-study-on-allocetra-ots-for-sepsis-key-insights-for-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","ISBC"],"gpt_icon":0},{"id":"2560510420","title":"Keros Therapeutics Gets FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2560510420","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560510420?lang=en_us&edition=fundamental","pubTime":"2025-08-20 22:10","pubTimestamp":1755699008,"startTime":"0","endTime":"0","summary":"Keros Therapeutics  said Wednesday that KER-065 was granted orphan drug designation by the US Food and Drug Administration for the treatment of Duchenne muscular dystrophy.Keros said it plans to advance the treatment to a phase 2 clinical trial.Price: 14.54, Change: +0.05, Percent Change: +0.35","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","KROS","BK4539","BK4139","BK4007"],"gpt_icon":0},{"id":"2560292101","title":"Keros Therapeutics granted Orphan Drug designation for KER-065 in DMD","url":"https://stock-news.laohu8.com/highlight/detail?id=2560292101","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560292101?lang=en_us&edition=fundamental","pubTime":"2025-08-20 21:55","pubTimestamp":1755698120,"startTime":"0","endTime":"0","summary":"Keros Therapeutics (KROS) announced the U.S. Food and Drug Administration granted Orphan Drug designation for KER-065 for the treatment of Duchenne...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/keros-therapeutics-granted-orphan-drug-designation-for-ker-065-in-dmd-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/keros-therapeutics-granted-orphan-drug-designation-for-ker-065-in-dmd-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","KROS","BK4539","BK4007"],"gpt_icon":0},{"id":"2560109848","title":"Intensity Therapeutics Is Maintained at Speculative Buy by Benchmark","url":"https://stock-news.laohu8.com/highlight/detail?id=2560109848","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560109848?lang=en_us&edition=fundamental","pubTime":"2025-08-20 21:10","pubTimestamp":1755695400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/INTS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 20, 2025 09:10 ET (13:10 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","INTS"],"gpt_icon":0},{"id":"2560106417","title":"Aligos Therapeutics appoints Ramon Polo as head of global regulatory affairs","url":"https://stock-news.laohu8.com/highlight/detail?id=2560106417","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560106417?lang=en_us&edition=fundamental","pubTime":"2025-08-20 20:45","pubTimestamp":1755693938,"startTime":"0","endTime":"0","summary":"Aligos Therapeutics (ALGS) announced the appointment of Ramon Polo as Senior Vice President, Head of Global Regulatory Affairs, effective immediate...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aligos-therapeutics-appoints-ramon-polo-as-head-of-global-regulatory-affairs-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aligos-therapeutics-appoints-ramon-polo-as-head-of-global-regulatory-affairs-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","BK4539","LENZ","BK4505","ALGS"],"gpt_icon":0},{"id":"2560010648","title":"Iterum Therapeutics Launches New Antibiotic ORLYNVAH","url":"https://stock-news.laohu8.com/highlight/detail?id=2560010648","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560010648?lang=en_us&edition=fundamental","pubTime":"2025-08-20 20:45","pubTimestamp":1755693934,"startTime":"0","endTime":"0","summary":"Iterum Therapeutics ( ($ITRM) ) has issued an update. On August 20, 2025, Iterum Therapeutics announced the U.S. commercial launch of ORLYNVAH™, an...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/iterum-therapeutics-launches-new-antibiotic-orlynvah?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/iterum-therapeutics-launches-new-antibiotic-orlynvah?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","LENZ","BK4539"],"gpt_icon":0},{"id":"2560105432","title":"Press Release: Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs","url":"https://stock-news.laohu8.com/highlight/detail?id=2560105432","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560105432?lang=en_us&edition=fundamental","pubTime":"2025-08-20 20:30","pubTimestamp":1755693000,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025  -- Aligos Therapeutics, Inc.  a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Ramón Polo, PharmD, PhD, MBA as Senior Vice President, Head of Global Regulatory Affairs, effective immediately.\"I am thrilled to welcome Ramón to the leadership team at Aligos,\" said Sushmita Chanda, PhD, DABT, Executive Vice President, Chief Development Officer at Aligos. \"As we progress ALG-000184 through the Phase 2 B-SUPREME study, Ramón's extensive regulatory expertise will be a critical component as we think about the future of the program. His experience driving global regulatory strategies will help guide Aligos at this pivotal time.\". \"I am excited to join the Aligos team as the company looks towards later-stage development,\" stated Ramón Polo, MBA, PharmD, PhD, Senior Vice President, Head of Global Regulatory Affairs at Aligos.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4559","IE00B42XCP33.USD","LU2430703095.HKD","LU1935042991.SGD","ALGS","LU1778281490.HKD","BK4504","IE00B1BXHZ80.USD","LU1032466523.USD","LU0203347892.USD","BK4568","IE000M9KFDE8.USD","BK4592","LU2129689605.HKD","LU2430703251.USD","IE0002270589.USD","LU0234572021.USD","LU0985320562.USD","LU1221951129.SGD","BK4534","LU1280957306.USD","LU1732800096.USD","LU0345769631.USD","IE00BJT1NW94.SGD","BK4532","SG9999001440.SGD","IE00BN8TJ469.HKD","LU1066051811.HKD","IE00BBT3K403.USD","JNJ","IE00BLSP4239.USD","LU0432979614.USD","BK4550","LU1221951046.USD","TISI","LU0058720904.USD","LU0882574055.USD","LU1196500208.SGD","IE00BFTCPJ56.SGD","IE00BGHQF631.EUR","IE00BJJMRZ35.SGD","LU2471134879.HKD","LU1732799900.SGD","LU2592432038.USD","LU2505996681.GBP","IE00B7SZLL34.SGD","LENZ","LU0795875169.SGD","LU2129689514.USD","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2560051871","title":"Press Release: HLS Therapeutics Announces New Credit Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2560051871","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560051871?lang=en_us&edition=fundamental","pubTime":"2025-08-20 20:30","pubTimestamp":1755693000,"startTime":"0","endTime":"0","summary":"-- CAD $79 million term loan replaces USD $56 million term loan. -- CAD $107 million  total facility provides enhanced. -- CAD-denominated facility reduces FX exposure and lowers interest rate. TORONTO, Aug. 20, 2025 /CNW/ - HLS Therapeutics Inc.  , a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that the company has entered into a new Credit Agreement  with National Bank of Canada  as administrative agent which provides for committed credit facilities denominated in Canadian dollars of up to CAD $107 million .National Bank serves as administrative agent and lead arranger, with the Toronto-Dominion Bank, Royal Bank of Canada, and Innovation Federal Credit Union as syndicate members. The Agreement replaced HLS's credit facility with JP Morgan Chase Bank, N.A. which had a maturity date of August 11, 2026. On closing, the proceeds from the new term facility were used to repay the Company's existing","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4139","N0Z.SI","BK6505","BK4539","BK6096","BK4007"],"gpt_icon":0},{"id":"2560105829","title":"Knight Therapeutics Gets Exchange Approval for Share Buyback Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2560105829","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560105829?lang=en_us&edition=fundamental","pubTime":"2025-08-20 20:15","pubTimestamp":1755692100,"startTime":"0","endTime":"0","summary":"Knight Therapeutics plans to launch a buyback program for up to roughly 3% of its issued and outstanding shares.The Canadian specialty pharmaceutical company said the Toronto Stock Exchange accepted its notice of intention to make a normal course issuer bid, under which it would be able to buy up to 3 million of its shares over a one-year period through Aug. 21, 2026.The Montreal-based company may purchase up to a daily maximum of 15,823 shares through the facilities of the TSX or an alternative Canadian trading system.Knight in the last 12 months has bought about 2 million of its shares under a prior normal course issuer bid approving the repurchase of up to 5.3 million shares.Knight's shares have risen 20% so far this year, last closing at C$6.39.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Knight Therapeutics Gets Exchange Approval for Share Buyback Program","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","BK4007","LENZ"],"gpt_icon":0},{"id":"2560105315","title":"Iterum Therapeutics announces U.S. commercial launch of ORLYNVAH","url":"https://stock-news.laohu8.com/highlight/detail?id=2560105315","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560105315?lang=en_us&edition=fundamental","pubTime":"2025-08-20 20:12","pubTimestamp":1755691926,"startTime":"0","endTime":"0","summary":"Iterum Therapeutics (ITRM) announced the U.S. commercial launch of ORLYNVAH oral tablets. The Food and Drug Administration approved ORLYNVAH for ad...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/iterum-therapeutics-announces-u-s-commercial-launch-of-orlynvah-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/iterum-therapeutics-announces-u-s-commercial-launch-of-orlynvah-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","ITRM","BK4539","BK4139","BK4007"],"gpt_icon":0},{"id":"2560039111","title":"Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2560039111","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560039111?lang=en_us&edition=fundamental","pubTime":"2025-08-20 20:00","pubTimestamp":1755691200,"startTime":"0","endTime":"0","summary":"FDA-approved antibiotic with the power of a penem in a novel oral formulation,offering a vital alternative in treating uncomplicated urinary tract infectionsDUBLIN and CHICAGO, Aug.  20, 2025  (GLOBE ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/20/3136342/0/en/Iterum-Therapeutics-launches-ORLYNVAH-the-first-and-only-oral-penem-antibiotic-in-the-U-S.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","BK4139","LENZ"],"gpt_icon":0},{"id":"2560103301","title":"Intensity Therapeutics price target lowered to $1.50 from $4 at Benchmark","url":"https://stock-news.laohu8.com/highlight/detail?id=2560103301","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560103301?lang=en_us&edition=fundamental","pubTime":"2025-08-20 19:45","pubTimestamp":1755690309,"startTime":"0","endTime":"0","summary":"Benchmark analyst Robert Wasserman lowered the firm’s price target on Intensity Therapeutics (INTS) to $1.50 from $4 and keeps a Speculative Buy ra...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/intensity-therapeutics-price-target-lowered-to-1-50-from-4-at-benchmark-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/intensity-therapeutics-price-target-lowered-to-1-50-from-4-at-benchmark-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"2560312295","title":"Prescient Therapeutics Releases Corporate Governance Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2560312295","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560312295?lang=en_us&edition=fundamental","pubTime":"2025-08-20 14:49","pubTimestamp":1755672545,"startTime":"0","endTime":"0","summary":"Prescient Therapeutics Limited ( ($AU:PTX) ) has shared an update. Prescient Therapeutics Limited has released its corporate governance statement f...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/prescient-therapeutics-releases-corporate-governance-statement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/prescient-therapeutics-releases-corporate-governance-statement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4539","BK4139","LENZ"],"gpt_icon":0},{"id":"2560122112","title":"Prescient Therapeutics Reports Financial Results with Focus on R&D Investment","url":"https://stock-news.laohu8.com/highlight/detail?id=2560122112","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560122112?lang=en_us&edition=fundamental","pubTime":"2025-08-20 14:47","pubTimestamp":1755672451,"startTime":"0","endTime":"0","summary":"Prescient Therapeutics Limited ( ($AU:PTX) ) has shared an update. Prescient Therapeutics Limited reported a decrease in interest revenue by 67.2% ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/prescient-therapeutics-reports-financial-results-with-focus-on-rd-investment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/prescient-therapeutics-reports-financial-results-with-focus-on-rd-investment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","LENZ","BK4007"],"gpt_icon":0},{"id":"2560122853","title":"Neurizon Therapeutics Says ALS Drug Candidate Study Confirms Long-Term Treatment at Recommended Dose is Safe, Well-Tolerated","url":"https://stock-news.laohu8.com/highlight/detail?id=2560122853","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560122853?lang=en_us&edition=fundamental","pubTime":"2025-08-20 14:45","pubTimestamp":1755672300,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics (ASX:NUZ) said the open-label extension study of NUZ-001, a drug candidate for the treatment of amyotrophic lateral sclerosis, or ALS, met its primary endpoint, confirming long-t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","NUZ.AU","LENZ","BK4007","BK4539","BK4139"],"gpt_icon":0},{"id":"2560124732","title":"Infant Bacterial Therapeutics Advances Toward Launch of Breakthrough Infant Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2560124732","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560124732?lang=en_us&edition=fundamental","pubTime":"2025-08-20 14:32","pubTimestamp":1755671573,"startTime":"0","endTime":"0","summary":"Infant Bacterial Therapeutics AB ( ($SE:IBT.B) ) has shared an announcement. Infant Bacterial Therapeutics AB reported no net sales for the first h...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/infant-bacterial-therapeutics-advances-toward-launch-of-breakthrough-infant-drug?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/infant-bacterial-therapeutics-advances-toward-launch-of-breakthrough-infant-drug?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LENZ","BK4539","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":16,"pageCount":4,"totalSize":318,"code":"91000000","status":"200"}]}}